Fibrocard, containing Verapamil, is generally used to help address symptoms related to heightened physiological activity across three major cardiovascular domains. The medication is commonly applied in conditions characterized by periods of heightened symptoms, including the sustained management of systemic hypertension, the management of episodic bursts of Supraventricular Tachyarrhythmias, and the supportive relief of recurrent Angina Pectoris (chest pain).

It provides supportive relief when symptoms interfere with routine activities, contributing to easing the overall symptom load. For patients managing these conditions, the medication helps address symptom clusters that may become intense or disruptive.

“The therapeutic approach with this medication is applied to support general well-being and functional stability during symptomatic periods.”

Therapeutic Focus: Symptom Clusters

Regulatory References

1. NIH MedlinePlus overview

Who can and cannot use Fibrocard?

The use of Fibrocard (Verapamil Hydrochloride) is defined by official regulatory eligibility rules, focusing on cardiac function, comorbidities, and age.

Eligibility Scope

Contraindicated Populations (Must Not Use): The medicine is strictly contraindicated for patients with severe left ventricular dysfunction or severe congestive heart failure. Absolute exclusion also applies to patients experiencing cardiogenic shock, marked hypotension (systolic pressure less than 90 mmHg), and those with specific conduction abnormalities, including Second- or Third-Degree AV block and Sick Sinus Syndrome, unless a functioning artificial pacemaker is present. Use is also prohibited in patients with Atrial flutter or Atrial fibrillation complicated by an accessory bypass tract (e.g., Wolff-Parkinson-White syndrome).

Conditional Use and Restrictions: Use requires caution in populations with hepatic impairment, as clearance is significantly reduced, potentially requiring a lower dose. Caution is also advised for patients with renal impairment and specific neuromuscular diseases. For the oral route, safety and efficacy have not been established in the pediatric population. Intravenous use is generally contraindicated in infants. Regarding reproductive status, use during pregnancy is advised only if the potential benefit justifies the risk (FDA Category C), and regulatory labels advise the discontinuation of nursing while taking the medicine.

Interactions with other medicines and products

The regulatory profile for Fibrocard (Verapamil Hydrochloride) documents interactions primarily stemming from its ability to inhibit the metabolic enzyme CYP3A4 and the transporter P-glycoprotein (P-gp), as well as its inherent cardiac activity. These interactions result in specific constraints and prohibitions described in official labeling.

Documented Interaction Patterns

Consumption-Based Cautions

The consumption of Grapefruit Juice is documented to significantly increase Fibrocard's plasma levels, and co-ingestion is generally discouraged by regulators. The herbal product St. John's Wort is noted to decrease drug exposure.

Modulating Calcium Influx and Myocardial Contraction

Fibrocard acts within the mechanistic domain of ion channel modulation by inhibiting the influx of calcium (Ca^2+) through L-type voltage-gated channels in the heart. This interference with the heart's electrical and contractile mechanisms results in a reduction in the force of heart muscle contraction (negative inotropy) and a decrease in myocardial oxygen consumption.

Slowing Cardiac Electrical Conduction

The drug engages mechanisms that regulate the heart's electrical conduction system, specifically by slowing down the passage of impulses through the Atrioventricular (AV) node. This modulation of the node's refractoriness affects electrical impulse propagation in nodal tissue, decreasing the frequency and conduction speed of electrical impulses through the cardiac tissue (negative chronotropy and dromotropy).

Decreasing Vascular Resistance

Fibrocard influences the biological system of vascular smooth muscle tone by blocking Ca^2+ entry into the arterial walls. This mechanistic cascade suppresses the final steps of muscle contraction, producing smooth muscle relaxation and peripheral vasodilation. This effect results in a reduction in systemic vascular resistance.

Fibrocard (Verapamil Hydrochloride) is administered via two primary routes: the Oral route for chronic, long-term management and the Intravenous (IV) injection route, which is strictly reserved for acute, high-monitoring use.

The dosing regimen varies significantly by form. Immediate-release (IR) tablets are typically prescribed in divided doses two to four times daily, with the total adult daily dose often ranging from 240 mg to 480 mg. Extended-release (ER) forms are intended for once-daily administration, often starting at 180 mg. Titration to the maximum dose (generally 480 mg/day) occurs gradually, often in weekly increments.

Oral administration involves specific intake instructions: ER tablets must be swallowed whole and must not be crushed or chewed to preserve their release mechanism. Some formulations are specified to be taken with food. Standard guidance includes avoiding the use of grapefruit juice while on this medication.

Special procedural conditions govern the IV use. The bolus dose (e.g., 5 mg to 10 mg) must be injected slowly over a minimum of two minutes under continuous ECG and blood pressure monitoring. Population-specific rules mandate that starting doses must be reduced and carefully titrated in patients with hepatic impairment, and IV administration in older adults requires a prolonged injection time of at least three minutes. If a dose is missed, standard instructions are to take it as soon as remembered, unless it is close to the next scheduled dose, in which case it should be skipped.

Fibrocard (Verapamil) was evaluated in research exploring several cardiovascular conditions. The information presented here focuses only on the official research base, including Randomized Controlled Trials (RCTs) and regulatory-reviewed studies, describing what the research explored and what has been observed so far, without providing any medical guidance.

Research Evidence for Fibrocard in High Blood Pressure (Systemic Hypertension)

Research for this condition includes large-scale Randomized Controlled Trials (RCTs) involving thousands of adults, including those with co-existing Coronary Artery Disease (CAD). These studies monitored changes in Blood Pressure (BP) and tracked the occurrence of major long-term cardiovascular events. Controlled studies reported findings describing patterns observed related to changes measured in BP values. Long-term event data is largely comparative (drug vs. drug), meaning the absolute benefit over no treatment is not defined by these trials.

Research Evidence for Fibrocard in Heart Rhythm Stabilization (Supraventricular Tachyarrhythmias)

The evidence comes from Controlled Clinical Studies, often in acute settings, monitoring outcomes describing episodic or acute changes in heart function. For Paroxysmal Supraventricular Tachycardia (PSVT), research describes patterns related to conversion to normal sinus rhythm. For Atrial Fibrillation or Flutter, studies indicate patterns related to the slowing of the ventricular rate, though conversion rates are low. Follow-up durations were often limited to the acute phase, and research exploring long-term prophylactic use is less extensive.

Research Evidence for Fibrocard in Chest Pain Relief (Angina Pectoris)

Fibrocard was evaluated in Placebo-Controlled Trials exploring outcomes related to physical discomfort such as recurrent angina. Researchers measured outcomes like patient exercise tolerance and the time to chest pain onset during standardized activity. Studies reported findings indicating patterns related to the duration of activity before discomfort. However, trials were short-term, and there is limited information on subsequent major cardiac events compared to long-term hypertension studies.

Evidence Gaps and Areas Under Study

The research base includes data for populations such as older adults and those with CAD. However, data for certain groups remain insufficient, particularly for pediatric or pregnant individuals, and the results apply only to the populations studied. A key limitation across the research is the focus on acute changes in rhythm issues versus long-term prevention, and the reliance on comparative evidence in long-term outcomes rather than direct placebo comparisons.

Key Studies & References

1. Antihypertensive and renoprotective effects of trandolapril/verapamil combination: a meta-analysis of randomized controlled trials

Common questions about Fibrocard (FAQ)

Q: Can I take this drug with Aspirin?

Regulatory documents mention that taking Fibrocard alongside aspirin has been associated in some reports with increased bleeding times. This means the blood may take longer to clot compared to when aspirin is taken alone. This information is based on official product labeling.

Q: Are there any dietary restrictions other than grapefruit juice?

Official product information notes that Fibrocard may affect how the body processes alcohol. Specifically, it may increase the concentration of alcohol in the bloodstream and prolong its intoxicating effects. This interaction is noted in official product information.

Q: How quickly does the immediate-release tablet start to work?

According to the official prescribing information, the immediate-release form of Fibrocard is designed to act relatively quickly. The medication typically reaches its highest concentration in the bloodstream, often referred to as Tmax, approximately 1 to 2 hours after you take the tablet by mouth.

The storage and disposal of Fibrocard must adhere to strict regulatory guidelines to maintain product stability and safety.

Official Storage Conditions

Fibrocard must be stored at Controlled Room Temperature, which ranges from 20 C to 25 C (68 F to 77 F). The product must be protected from light and moisture and should not be stored above 30 C. The medicine must be kept in its original container and the container must remain tightly closed.

Child Safety and Disposal

For safety, Fibrocard must be kept out of the reach and sight of children.

Disposal of unused or expired product must follow local regulatory requirements for pharmaceutical waste. The medication must not be disposed of in household wastewater or general trash, as instructed by governmental agencies.